AU7479596A - Induction of immunological tolerance - Google Patents

Induction of immunological tolerance

Info

Publication number
AU7479596A
AU7479596A AU74795/96A AU7479596A AU7479596A AU 7479596 A AU7479596 A AU 7479596A AU 74795/96 A AU74795/96 A AU 74795/96A AU 7479596 A AU7479596 A AU 7479596A AU 7479596 A AU7479596 A AU 7479596A
Authority
AU
Australia
Prior art keywords
tissue
implanted
cell
induction
organs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU74795/96A
Other languages
English (en)
Inventor
Paul P. Latta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU7479596A publication Critical patent/AU7479596A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
AU74795/96A 1995-10-26 1996-10-25 Induction of immunological tolerance Abandoned AU7479596A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US587795P 1995-10-26 1995-10-26
US005877 1995-10-26
PCT/US1996/017234 WO1997015243A1 (en) 1995-10-26 1996-10-25 Induction of immunological tolerance

Publications (1)

Publication Number Publication Date
AU7479596A true AU7479596A (en) 1997-05-15

Family

ID=21718169

Family Applications (1)

Application Number Title Priority Date Filing Date
AU74795/96A Abandoned AU7479596A (en) 1995-10-26 1996-10-25 Induction of immunological tolerance

Country Status (6)

Country Link
US (5) US20020192190A1 (enExample)
EP (2) EP1586284B1 (enExample)
AT (2) ATE297702T1 (enExample)
AU (1) AU7479596A (enExample)
DE (2) DE69634859D1 (enExample)
WO (1) WO1997015243A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69634859D1 (de) * 1995-10-26 2005-07-21 Paul P Latta Induktion von immunologischer toleranz
WO2000054786A1 (en) * 1999-03-15 2000-09-21 Modex Therapeutiques, S.A. Methods and compositions for tolerizing hosts for long term survival of tissue transplants
US20020012667A1 (en) * 2000-05-16 2002-01-31 Mcmichael John Method for preventing allograft rejection
CA2662209C (en) * 2006-08-29 2015-02-17 The University Of Akron Implantable devices for producing insulin
WO2008079997A2 (en) * 2006-12-22 2008-07-03 Medtronic, Inc. Implantable device, angiogenesis mechanism and methods
JP5719171B2 (ja) * 2007-10-15 2015-05-13 フレゼニウス メディカル ケア ドイッチェランド ゲゼルシャフト ミット ベシュレンクテル ハフツング 内皮細胞移植、特に膵島移植による糖尿病の処置におけるアジュバント活性を有する医薬を調製するための微小胞（ｍｖ）の使用、および関連方法
US9446168B2 (en) 2010-06-07 2016-09-20 Beta-O2 Technologies Ltd. Multiple-layer immune barrier for donor cells
US9540630B2 (en) * 2008-09-17 2017-01-10 Beta O2 Technologies Ltd. Optimization of alginate encapsulation of islets for transplantation
EP2470228B1 (en) 2009-08-28 2017-10-04 Sernova Corporation Methods and devices for cellular transplantation
CA3039653A1 (en) 2016-10-05 2018-04-12 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and systems for augmenting immune system responses
US10973956B2 (en) * 2017-01-05 2021-04-13 The Regents Of The University Of Michigan Microporous hydrogel scaffolds for cell transplantation

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4298002A (en) 1979-09-10 1981-11-03 National Patent Development Corporation Porous hydrophilic materials, chambers therefrom, and devices comprising such chambers and biologically active tissue and methods of preparation
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4378016A (en) 1981-07-15 1983-03-29 Biotek, Inc. Artificial endocrine gland containing hormone-producing cells
CA1196862A (en) 1983-06-01 1985-11-19 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US4689293A (en) 1983-06-06 1987-08-25 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US4806355A (en) 1983-06-06 1989-02-21 Connaught Laboratories Limited Microencapsulation of living tissue and cells
EP0147939A2 (en) 1983-11-15 1985-07-10 JOHNSON & JOHNSON Implantable module for gylcemia regulation
NO166836C (no) 1985-03-14 1991-09-11 Univ California Fremgangsmaate for behandling av et organtransplantat.
US4997443A (en) 1985-08-26 1991-03-05 Hana Biologics, Inc. Transplantable artificial tissue and process
US4902295A (en) 1985-08-26 1990-02-20 Hana Biologics, Inc. Transplantable artificial tissue
GB8608068D0 (en) * 1986-04-02 1986-05-08 Cobbold S P Monoclonal antibodies
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5182111A (en) 1987-11-17 1993-01-26 Boston University Research Foundation In vivo delivery of active factors by co-cultured cell implants
JP3117994B2 (ja) 1990-05-16 2000-12-18 ベイラー・カレツジ・オブ・メデイシン 永久的ヒト肝細胞の細胞系および肝臓補助装置（ｌａｄ）におけるその使用
US5529914A (en) * 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
CA2034641A1 (en) 1990-11-27 1992-05-28 Gudmund Skjak-Braek Homologous guluronic acid alginate coating composition for in-vivo application and implatation and method of using same
SG47470A1 (en) 1991-04-25 1998-04-17 Univ Brown Res Found Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products
GB9120776D0 (en) 1991-10-01 1991-11-13 Shell Int Research Process for upgrading a hydrocarbonaceous feedstock and apparatus for use therein
US5425764A (en) * 1992-07-30 1995-06-20 The University Of Toledo Bioartificial pancreas
US5262055A (en) * 1992-10-19 1993-11-16 The University Of Utah Implantable and refillable biohybrid artificial pancreas
WO1995003062A1 (en) * 1993-07-21 1995-02-02 Cellpro, Incorporated Methods and compositions for preventing immune rejection of solid organ grafts
US6703017B1 (en) * 1994-04-28 2004-03-09 Ixion Biotechnology, Inc. Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US5629194A (en) * 1994-10-21 1997-05-13 Diacrin, Inc. Isolated porcine pancreatic cells for use in treatment of diseases characterized by insufficient insulin activity
DE69634859D1 (de) * 1995-10-26 2005-07-21 Paul P Latta Induktion von immunologischer toleranz

Also Published As

Publication number Publication date
US7361333B2 (en) 2008-04-22
US20100260816A1 (en) 2010-10-14
US20020192190A1 (en) 2002-12-19
EP0955948B1 (en) 2005-06-15
US7361334B2 (en) 2008-04-22
EP1586284A1 (en) 2005-10-19
DE69637842D1 (de) 2009-04-02
US20040047848A1 (en) 2004-03-11
US20080317770A1 (en) 2008-12-25
ATE422857T1 (de) 2009-03-15
US20040191227A1 (en) 2004-09-30
EP0955948A4 (enExample) 1999-11-17
ATE297702T1 (de) 2005-07-15
EP0955948A1 (en) 1999-11-17
DE69634859D1 (de) 2005-07-21
WO1997015243A1 (en) 1997-05-01
EP1586284B1 (en) 2009-02-18

Similar Documents

Publication Publication Date Title
ATE308926T1 (de) Nicht antigenische und durch peressigsäure vernetzte transplantate mit innerer kollagenschicht
DK0920322T3 (da) Anvendelser af modificeret autologt blod til behandling af autoimmunitetssygdomme
AU6649996A (en) Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
GB9400163D0 (en) Membrane
AU1369297A (en) Medical implant
WO2003076604A3 (en) Surgical device for skin therapy or testing
DE69714083D1 (de) Die verwendung von lactoperoxidase, einem peroxiddonor und thiocyanat zur herstellung eines medikaments zur behandlung einer infektion mit helicobacter pylori
CA2156506A1 (fr) Prothese destinee au traitement d'une lumiere ou voie naturelle, notamment prothese endo-urethrale
NO933842L (no) Implanterbar, bioforenelig, immunoisolatorisk b{rer for angivelse av valgte terapeutiske produkter
CA2234233A1 (en) Retrievable bioartificial implants
CA2284079A1 (en) Immunotoxins and methods of inducing immune tolerance
EP0955948A4 (enExample)
Goodman Does the immune system play a role in loosening and osteolysis of total joint replacements?
BR9612821A (pt) Métodos para a prevenção de rejeição de enxerto em transplante e para a produção de uma célula de hospedeiro para terapia genética universal
KR950700079A (ko) 이식체-대-숙주 질환을 억제하기 위한 인터루킨-10의 용도(Use of interleukin-10 to suppress graft-vs. -host disease)
WO2024151852A3 (en) Devices and methods of a medicament-producing implantable matrix
Fabre Epidermal allografts
WO1996032137A3 (en) Methods of inducing immune tolerance using immunotoxins
CA2194485A1 (en) Endothelial lining effects and treatment of vasospastic disorders
WO2003054150A3 (en) Apoptotic ebv-transformed lymphocytes, a therapeutic agent for post-transplant lymphoproliferative disorder
ES2002127A6 (es) Procedimiento para extraer los colagenos placentarios
ATE261735T1 (de) Verwendung von wirkstoffen zur herstellung von arzeinmitteln zur behandlung der rheumatischen arthritis
Beales Otosclerosis—past and present
Muelder Wounds that will not heal: the Buruli ulcer.
EP0959899A4 (en) LO-CD2a antibodies and their use to inhibit T-cell activation and proliferation